Patient-reported factors influencing the treatment decision-making process of older women with non-metastatic breast cancer: a systematic review of qualitative evidence
ConclusionsThis systematic review highlights the complexity of factors that influence an older woman ’s treatment decision-making process. Acknowledging and addressing these factors may improve discussions about treatment choices between older women and their health care providers, and encourage maximization of a patient-centered approach. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Protein N-glycosylation alteration and glycolysis inhibition both contribute to the antiproliferative action of 2-deoxyglucose in breast cancer cells
ConclusionN-linked glycosylation interference and glycolysis disruption both contribute to the anticancer properties of 2-DG in breast cancer cells. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy
AbstractPurposeApproximately 25% of breast cancer patients experience treatment delays or discontinuation due to paclitaxel-induced peripheral neuropathy (PN). Currently, there are no predictive biomarkers of PN. Pharmacometabolomics is an informative tool for biomarker discovery of drug toxicity. We conducted a secondary whole blood pharmacometabolomics analysis to assess the association between pretreatment metabolome, early treatment-induced metabolic changes, and the development of PN.MethodsWhole blood samples were collected pre-treatment (BL), just before the end of the first paclitaxel infusion (EOI), and 24 h after...
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Screening mammography: benefit of double reading by breast density
ConclusionsSingle reading decreased sensitivity as compared with double reading across all BI-RADS density codes. This included results based on consensus BI-RADS density codes. This means that replacement of double with single reading would have negative consequences for the screened women, even if density could be assessed automatically calibrated to the usual consensus level. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Endocrine therapy use in the twenty-first century: usage rates and temporal trends illustrate opportunities for improvement for South Carolina Medicaid women
This study examines endocrine therapy (ET) non-initiation, non-adherence, and duration by age, race, temporal trend for South Carolina Medicaid-enrolled women diagnosed with estrogen receptor-positive breast cancer between 2000 and 2014 (N = 3830).MethodsAge, race, relative risk, and median duration of ET use were compared. Temporal trends in ET non-initiation, non-adherence, and duration were observed using linear and logistic regression models, controlling for age and race.ResultsFifty-three percent of women in the sample did not initiate ET, with highest non-initiation rates among African Americans and sur...
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Availability of prior mammograms affects incomplete report rates in mobile screening mammography
ConclusionsIncomplete reports were more frequent in mobile mammography than the fixed site. The availability of prior comparison mammograms at time of interpretation decreased the rate of incomplete mammogram reports. Recall rates were higher without prior comparison mammograms and lowest when comparison FFDM mammograms were available. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

A pilot study of a breast surgery Enhanced Recovery After Surgery (ERAS) protocol to eliminate narcotic prescription at discharge
AbstractBackgroundThe evolving conceptualization of the management of surgical pain was a major contributor to the supply of narcotics that led to the opioid crisis. We designed and implemented a breast surgery-specific Enhanced Recovery After Surgery (ERAS) protocol using opioid-sparing techniques to eliminate narcotic prescription at discharge without sacrificing perioperative pain control.MethodsA pilot observational study included patients with and without cancer undergoing lumpectomy. The convenience sample consisted of an ERAS group and a control usual care (UC) group who underwent surgery during the same time period...
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03
ConclusionBasal HER2 phenotype showed poor DFS, but equivalent pCR rate after concurrent neo-adjuvant chemotherapy with trastuzumab. A different treatment approach to basal-HER2 type is needed even for cases that achieved adequate clinical response after NAC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Breast cancer and its impact in male transsexuals
ConclusionReviewing the literature, so many different data concerning probability of breast cancer in sexual minority can be found. Breast cancer screening program should be offered to all transgender individuals according to national guidelines. Very important is to take into consideration a transgender person ’s natal and surgical anatomy, unique clinical concerns for depression and anxiety, risk of suicide together with risk factors including experiences of harassment or physical or sexual violence, low education level, and unemployment. Understanding the need for mammography in these often marginaliz ed groups is...
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Granulomatous mastitis: etiology, imaging, pathology, treatment, and clinical findings
ConclusionAlthough clinical and radiological findings of patients with GM may mimic those of breast carcinoma, our study showed that women of childbearing age, especially among Hispanic ethnicity with a recent history of pregnancy or high prolactin level and newly tender mass-like lesion, in addition to new focal asymmetry on mammogram and heterogeneous hypoechoic irregular-shaped mass on ultrasound exam, should raise concern for GM. Non-invasive approach and clinical follow-up were the preferred treatment method. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Extremely brief mindfulness interventions for women undergoing breast biopsies: a randomized controlled trial
AbstractPurposeMindfulness-based programs can reduce stress and help practitioners to have positive attitudes in their daily lives. This randomized controlled trial evaluated the impact of brief Mindfulness interventions on quantitative and qualitative stress parameters in patients undergoing imaging-guided breast biopsies.MethodsEighty-two women undergoing percutaneous imaging-guided breast biopsy were randomized into two groups: MBI group or standard care group. One week before the biopsy procedure, on the waiting room and during the biopsy procedure, the MBI group was exposed to mindfulness techniques and the standard c...
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy
This study evaluated predictive factors for recovery of ovarian function after ovarian protection by GnRH agonist during chemotherapy in young breast cancer patients.MethodsThis prospective cohort study analyzed 105 young breast cancer patients who were studied longitudinally after receiving GnRH agonist during cyclophosphamide-based chemotherapy for ovarian protection. Associations between pretreatment hormones, clinical factors, and recovery of ovarian function (resumption of menstruation or anti-M üllerian hormone (AMH) ≥ 1 ng/ml) were evaluated at 12 months and long-term follow-up after compl...
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study
AbstractPurposePreliminary data suggest that high expression of the TR β1 tumor suppressor is associated with longer survival among women with early breast cancer. We undertook this study to validate these findings.MethodsIn this prospective cohort study, we analyzed the prognostic significance of TR β1 protein expression in the breast tumors of 796 women who had undergone breast surgery in the Henrietta Banting Breast Cancer database. All women were recruited after undergoing primary surgical therapy at Women’s College Hospital (Toronto, ON, Canada) between January 1987 and December 2000. De tails regardin...
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Estrogen-receptor status and risk of contralateral breast cancer following DCIS
ConclusionsThis finding suggests that ER+  DCIS may represent a field effect that confers increased propensity for developing cancer across breast tissue, regardless of laterality. In contrast, ER− DCIS may represent an isolated local event. Given that the majority of DCIS is ER+, and only a minority of DCIS patients receive hormonal th erapy, consideration of ER status may influence treatment and surveillance approaches. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Dosimetric study to assess the feasibility of intraoperative radiotherapy with electrons (ELIOT) as partial breast irradiation for patients with cardiac implantable electronic device (CIED)
AbstractPurposeTo report in-vivo dosimetry in the infraclavicular region, a potential site of a cardiac implantable electronic device (CIED) and to evaluate the absorbed dose from intraoperative radiotherapy with electrons (ELIOT).Methods27 non-cardiopathic breast cancer (BC) patients without CIED received quadrantectomy and ELIOT as partial breast irradiation. Before delivering ELIOT, two catheters, each containing eight thermoluminescent dosimeters (TLDs), were positioned in the infraclavicular region. TLDs internal catheter was located deep in the tumor bed while the external catheter was placed on patient ’s skin...
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort
In this study, we evaluated the prognostic value of this new staging system compared to the previous AJCC 7th edition staging system.MethodsWe conducted a retrospective analysis of women with stage I, II, or III BC who underwent curative surgery with/without adjuvant systemic therapy at Samsung Medical Center between July 2004 and December 2008.ResultsOf 3,208 BCs, this study was analyzed using the information of 2,790  BC patients. Hormone receptor-positive (HR+) and human epidermal growth factor 2 (HER2)− BCs were observed in 62.9% of BCs, HR+/ HER2+ in 9.3%, HR−/HER2− in 17.0%, and HR&minus...
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis
ConclusionIn postmenopausal women with estrogen and/or progesterone receptor-positive advanced breast cancer, fulvestrant 500  mg showed better efficacy than aromatase inhibitor, which was not seen with fulvestrant 250 mg. Compared to aromatase inhibitors, fulvestrant prolonged time to progression/progression-free survival in the subgroups including estrogen and progesterone receptor-positive patients and those aged ≥  65 years. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling
ConclusionAdjuvant treatment with docetaxel (CD  ≥ 400 mmg/m2) is associated with a significant rate of grade 2 PA, leading to wearing a wig, in around 10% of patients. This toxicity was completely prevented with scalp cooling. Clinical Trial Reference: NCT00515762. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy
ConclusionsHot flash severity during tamoxifen therapy can not be accounted for byCYP2D6 genotype or observed plasma concentration of tamoxifen, 4-hydroxytamoxifen, or endoxifen. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling
In the original publication of the article, Table  1 was published with incorrect caption and values. The Table 1 with corrected caption and values is given in this Correction. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 31, 2018 Category: Cancer & Oncology Source Type: research

Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy
ConclusionsThe combination of alpelisib and T-DM1 is tolerable and demonstrates activity in trastuzumab-resistant HER2-positive MBC. Furthermore, activity was observed in T-DM1-resistant disease. These data suggest that PIK3CA inhibition targets an important resistance pathway to anti-HER2 therapy, providing rationale for further study of PI3K inhibition in refractory HER2-positive MBC to validate these results. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 3, 2018 Category: Cancer & Oncology Source Type: research

Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes
ConclusionOur data suggest that inability to maintain normal weight during NAC is a predictive marker of poor survival but not pCR. It may be important for patients to maintain a normal weight during NAC. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 3, 2018 Category: Cancer & Oncology Source Type: research

The combined presence of CD20  + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome
AbstractPurposeThe purpose of the study was to evaluate protein expression of PD-L1 and CD20 as prognostic biomarkers of patient outcome in inflammatory breast cancer (IBC) samples.MethodsPD-L1 and CD20 protein expression was measured by immunohistochemistry in 221 pretreatment IBC biopsies. PD-L1 was assessed in tumor cells (PD-L1+ tumor cells) and tumor stromal infiltrating lymphocytes (PD-L1+ TILs); CD20 was scored in tumor-infiltrating B cells. Kaplan –Meier curves and Cox proportional hazard models were used for survival analysis.ResultsPD-L1+ tumor cells, PD-L1+ TILs, and CD20+ TILs were found in 8%, 66%, and 6...
Source: Breast Cancer Research and Treatment - August 3, 2018 Category: Cancer & Oncology Source Type: research

Mortality after contralateral breast cancer in Denmark
AbstractPurposeHow a second breast cancer diagnosis affects survival in comparison with unilateral breast cancer (UBC) is unclear. Prognostic factors for contralateral breast cancer (CBC) are also not well established. We aimed to investigate the survival pattern after CBC with particular focus on time between first and second breast cancer diagnosis and age at CBC diagnosis.MethodsWithin the nationwide Danish Breast Cancer Cooperative Group database, we identified 68,466 breast cancer patients diagnosed during 1978 –2012. Patients who subsequently developed CBC were identified in a previously established database (N...
Source: Breast Cancer Research and Treatment - August 3, 2018 Category: Cancer & Oncology Source Type: research

New emerging roles of microRNAs in breast cancer
ConclusionThe information presented in this review is important to encourage new directed studies that consider microRNAs as a good tool to improve the diagnostic and treatment alternatives in breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 3, 2018 Category: Cancer & Oncology Source Type: research

High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival
AbstractPurposeMetastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has been identified as a prognostic marker for the metastasis of early-stage non-small cell lung cancer (NSCLCs). We studiedMALAT1 expression in breast cancer in relation to disease features and patient survival.MethodsQuantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was used to measureMALAT1 expression in tumor samples of 509 breast cancer patients. Hazards ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the association betweenMALAT1 expression and breast cancer survival using the Cox proportional...
Source: Breast Cancer Research and Treatment - August 3, 2018 Category: Cancer & Oncology Source Type: research

Intratumoral heterogeneity on dedicated breast positron emission tomography predicts malignancy grade of breast cancer
AbstractPurposeDedicated breast positron emission tomography (DbPET) provides detailed high-resolution images and can detect intratumoral heterogeneity using18F-fluorodeoxyglucose (FDG). We aimed to evaluate the correlation between FDG uptake on DbPET and the clinicopathological features of breast cancer, particularly those with an intratumoral heterogeneous distribution of FDG on DbPET.MethodsWe evaluated 195 consecutive patients with invasive breast cancer who underwent preoperative whole-body PET (WBPET) and DbPET concurrently between January 2016 and March 2017. The relationships between clinicopathological factors and...
Source: Breast Cancer Research and Treatment - August 3, 2018 Category: Cancer & Oncology Source Type: research

Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system
ConclusionThe LUM Imaging System allows rapid identification of residual tumor in the lumpectomy cavity of breast cancer patients and may reduce rates of positive margins. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 3, 2018 Category: Cancer & Oncology Source Type: research

Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers
ConclusionThis matched analysis of a large number ofBRCA mutation carriers suggests that age at first birth has little influence onBRCA1 orBRCA2 breast cancer risk. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 3, 2018 Category: Cancer & Oncology Source Type: research

Association between sleep disorders and the presence of breast cancer metastases in gynecological practices in Germany: a case –control study of 11,412 women
ConclusionA positive association was found between sleep disorders and the presence of metastases in women diagnosed with breast cancer in gynecological practices in Germany. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 3, 2018 Category: Cancer & Oncology Source Type: research

Validation of the newly proposed American Joint Committee on Cancer (AJCC) breast cancer prognostic staging group and proposing a new staging system using the National Cancer Database
AbstractBackgroundThe eighth edition of AJCC cancer staging manual incorporated biomarker status into the prognostic staging group (PSG). We used data from National Cancer Database (NCDB) to validate and improve the PSG.MethodsAll patients had surgery and at least some systemic treatment (endocrine therapy, chemotherapy or HER2 targeted therapy). Information from 420,520 patients was assessed for potential predictors of overall survival (OS), including age at diagnosis (age), tumor grade (G), hormonal receptor and HER2 status, and presence of lymph vascular invasion (LVI), stratified by stage or sub-stages. Based on the mu...
Source: Breast Cancer Research and Treatment - August 3, 2018 Category: Cancer & Oncology Source Type: research

Evolving surgical treatment decisions for male breast cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database
ConclusionAnalysis of this large, prospective multi-institutional cohort revealed that complication rates are low and comparable to reported rates in the female breast cancer population. What is also significant about this analysis is that the cohort demonstrated the importance of cosmetic considerations in MBC patients, as some men decide to undergo breast-conserving surgery or immediate breast reconstruction. Contralateral prophylactic mastectomy in the treatment of MBC is also performed. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 3, 2018 Category: Cancer & Oncology Source Type: research

Risk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effect
We examined the rates ofBRCA testing and RRBM from 1997 to 2016, and quantified trends before and after the Jolie op-ed.MethodsThis observational study of insurance claims data representative of the commercially-insured US population (Truven MarketScan ® database) measuredBRCA testing and RRBM rates among females  ≥ 18 years. Censoring events were breast cancer or ovarian cancer diagnosis, last follow-up date (September 2016), or death. Interrupted time series analyses were used to quantify trends before and after the op-ed.ResultsAngelina Jolie ’sNYT op-ed led to a statistically significant...
Source: Breast Cancer Research and Treatment - August 3, 2018 Category: Cancer & Oncology Source Type: research

The relationship between tumour size and nodal status is more incompatible in triple-negative tumours
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 3, 2018 Category: Cancer & Oncology Source Type: research

Rebuttal comments on “Glucocorticoids in breast cancer treatment: Real benefit or selection bias?”
(Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - August 2, 2018 Category: Cancer & Oncology Source Type: research

Concurrent risk-reduction surgery in patients with increased lifetime risk for breast and ovarian cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database
AbstractBackgroundPatients with genetic susceptibility to breast and ovarian cancer are eligible for risk-reduction surgery. Surgical morbidity of risk-reduction mastectomy (RRM) with concurrent bilateral salpingo-oophorectomy (BSO) is unknown. Outcomes in these patients were compared to patients undergoing RRM without BSO using a large multi-institutional database.MethodsA retrospective cohort analysis was conducted using the American College of Surgeon ’s National Surgical Quality Improvement Program (NSQIP) 2007–2016 datasets, comparing postoperative morbidity between patients undergoing RRM with patients un...
Source: Breast Cancer Research and Treatment - July 13, 2018 Category: Cancer & Oncology Source Type: research

Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer
ConclusionWe did not detect significant changes in AHT use after the HDHP switch. Findings might be related to modest increases in overall AHT OOP costs, the availability of low-cost generic tamoxifen, and patient awareness that AHT can prolong life and health. Minimizing OOP cost increases for essential medications might represent a feasible approach for maintaining medication adherence among HDHP members with incident breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 13, 2018 Category: Cancer & Oncology Source Type: research

Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
ConclusionsPalbociclib in combination with endocrine therapy shows an unexpectedly high CBR and favorable safety profile in heavily pretreated endocrine-resistant estrogen receptor-positive, HER2-negative MBC patients. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - July 13, 2018 Category: Cancer & Oncology Source Type: research

Predictors of surveillance mammography outcomes in women with a personal history of breast cancer
This study was HIPAA compliant and IRB approved. We performed an electronic medical record review for a cohort of women with American Joint Committee on Cancer (AJCC) Stage I or II invasive breast cancer treated with breast conservation therapy who developed subsequent in-breast treatment recurrence (IBTR) or contralateral breast cancer (CBC). Poor surveillance outcome was defined as second breast cancer not detected by surveillance mammography, including interval cancers (diagnosed within 365  days of surveillance mammogram with negative results) and clinically detected cancers (diagnosed without a surveillance mammo...
Source: Breast Cancer Research and Treatment - July 13, 2018 Category: Cancer & Oncology Source Type: research

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial
AbstractPurposeAromatase inhibitor-associated musculoskeletal symptoms (AIMSS) are common adverse events of AIs often leading to drug discontinuation. We initiated a prospective clinical trial to evaluate whether bisphosphonates are associated with reduced incidence of AIMSS.MethodsIn the single-arm trial, the Zoledronic Acid Prophylaxis (ZAP) trial, we compared the incidence of AIMSS against historical controls from the Exemestane and Letrozole Pharmacogenomics (ELPh) trial. Eligible women were postmenopausal with stage 0-III breast cancer planning to receive adjuvant AIs. AIMSS was assessed using the Health Assessment Qu...
Source: Breast Cancer Research and Treatment - July 13, 2018 Category: Cancer & Oncology Source Type: research

Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system
This study included 3382 women from the Pathways Study diagnosed from 2005 to 2013 with stages I –III hormone receptor-positive BC and who responded to the Medical Outcomes Study Social Support and Interpersonal Processes of Care surveys, approximately 2 months post-diagnosis. We used logistic regression to evaluate associations between tertiles of social support and non-initiation (
Source: Breast Cancer Research and Treatment - June 28, 2018 Category: Cancer & Oncology Source Type: research

Physician peer group characteristics and timeliness of breast cancer surgery
ConclusionsThe likelihood of surgical delay varied substantially across physician peer groups and was associated with provider density and patient racial composition. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 28, 2018 Category: Cancer & Oncology Source Type: research

Understanding racial/ethnic differences in breast cancer-related physical well-being: the role of patient –provider interactions
AbstractPurposeRacial/ethnic differences in cancer symptom burden are well documented, but limited research has evaluated modifiable factors underlying these differences. Our objective was to examine the role of patient –provider interactions to help explain the relationship between race/ethnicity and cancer-specific physical well-being (PWB) among women with breast cancer.MethodsThe Pathways Study is a prospective cohort study of 4505 women diagnosed with breast cancer at Kaiser Permanente Northern California between 2006 and 2013. Our analysis included white, black, Hispanic, and Asian participants who completed ba...
Source: Breast Cancer Research and Treatment - June 28, 2018 Category: Cancer & Oncology Source Type: research

FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment
ConclusionsThere is good correlation between the somatic mutations and CNA called using archived blood or normal breast tissue as germline reference material. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 28, 2018 Category: Cancer & Oncology Source Type: research

Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
AbstractPurposeThe aim of this study was to confirm the therapeutic role of eribulin on Taiwanese women with metastatic breast cancer.MethodsThis retrospective study examined 449 females who received eribulin between March 2014 and June 2017 at 14 hospitals in Taiwan for treatment of locally advanced or metastatic breast cancer.ResultsThe survival rate at 24  months was 57.2% (95% CI 51.0–62.9%) and the median time to treatment failure (TTF) was 3.91 months (95% CI 3.45–3.94). A total of 175 patients (40.1%) received eribulin for fewer than 90 days and the others received it for 90 days or m...
Source: Breast Cancer Research and Treatment - June 28, 2018 Category: Cancer & Oncology Source Type: research

A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation
ConclusionsThe addition of ruxolitinib to capecitabine for patients with advanced breast cancer and high systemic inflammation was generally tolerable; ORR was numerically greater, a more favorable change in HRQoL was observed, but neither OS nor PFS was improved compared with placebo plus capecitabine. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 28, 2018 Category: Cancer & Oncology Source Type: research

Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews
ConclusionsUptake of tamoxifen is low in clinical practice. There were no socio-demographic differences in uptake, suggesting that the introduction of breast cancer preventive therapy is unlikely to create socioeconomic inequalities in cancer incidence. Women ’s decision-making was influenced by familial priorities, particularly having children. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 28, 2018 Category: Cancer & Oncology Source Type: research

Association of reproductive history with breast tissue characteristics and receptor status in the normal breast
ConclusionReproductive risk factors significantly influence the epithelial tissue compartment and expression of hormone receptors in later life. These changes remain after menopause. This study provides deeper insights of the biological mechanisms by which reproductive history influences epithelial area and expression of hormone receptors, and as a consequence the risk of breast cancer. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 28, 2018 Category: Cancer & Oncology Source Type: research

MCP-1 is overexpressed in triple-negative breast cancers and drives cancer invasiveness and metastasis
ConclusionOur study suggests that MCP-1 mediated pathways could be potential therapeutic targets for the treatment of TNBC, and could reduce cancer health disparities. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 28, 2018 Category: Cancer & Oncology Source Type: research

Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy
ConclusionsAssessing nearly 14,000 women from a contemporary United States database, this is the largest known study examining the relationship between response to NC and molecular subtype. Women with luminal A disease are the least likely to undergo pCR, with the highest rates in Her2 disease. Degree of response is associated with OS, especially in luminal B, Her2, and TN patients. Despite the comparatively higher likelihood of achieving pCR in TN cases, this subgroup may still experience a survival detriment, which has implications for an ongoing national randomized trial. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - June 28, 2018 Category: Cancer & Oncology Source Type: research